

PATENT COOPERATION TREATY




PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	(10111110)	e 30 and Rule 70)				
Applicant's or agent's file reference DF8691/PCT	FOR FURTHER A	CTION	See Form PCT/IPEA/416			
International application No.		ate (day/month/year)	Priority date (day/month/year)			
		03 (08.10.2003)	11 October 2002 (11.10.2002)			
International Patent Classification (IPC) or national classification and IPC A61K 31/198, A61P 9/00, 25/28, 43/00						
Applicant KOGA, Yasutoshi						
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 						
2. This REPORT consists of a total of 4 sheets, including this cover sheet.						
3. This report is also accompanied by ANNEXES, comprising:						
a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:						
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
4. This report contains indications relating to the following items:						
Box No. I Basis of the report						
Box No. II Priority						
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
Box No. IV Lack of unity of invention						
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certain documents cited						
Box No. VII Certain defects in the international application						
Box No. VIII Certain observations on the international application						
Date of submission of the demand		Date of completion of this report				
04 March 2004 (04.03.2004)		01 July 2004 (01.07.2004)				
Name and mailing address of the IPEA/JP		Authorized officer				
Facsimile No.		Telephone No.				





INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY PCT/JP2003/012891 Box No. 1 Basis of the report 1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item. This report is based on translations from the original language into the following language which is language of a translation furnished for the purpose of: international search (under Rules 12.3 and 23.1(b)) publication of the international application (under Rule 12.4) international preliminary examination (under Rules 55.2 and/or 55.3) 2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report): The international application as originally filed/furnished the description: pages , as originally filed/furnished pages* received by this Authority on pages* received by this Authority on the claims: pages , as originally filed/furnished pages* , as amended (together with any statement) under Article 19 pages* received by this Authority on pages* received by this Authority on the drawings: pages , as originally filed/furnished pages* received by this Authority on received by this Authority on a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing. The amendments have resulted in the cancellation of: the description, pages the claims, Nos. the drawings, sheets/figs _____ the sequence listing (specify): __ any table(s) related to sequence listing (specify): _____ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)). the description, pages __ the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify):

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Internation lication No.

PCT/JP 03/12891

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

1.	Statement -			
	Novelty (N)	Claims	_	YES
		Claims	1-6	NO
	Inventive step (IS)	Claims		YES
	Claims	1-6	NO	
Industrial applicability (IA)	Claims	1-6	YES	
	Claims		NO	

2. Citations and explanations

- Document 1: Database CAPLUS on STN, AN 1999:326370, DN 131:111175; L. Ye et al., "Effect of L-arginine on protection of myocardial structure", Zhonghua Chuangshang Zazhi, 1999, Vol. 15, No. 2, pp. 124-126
- Document 2: Database CAPLUS on STN, AN 2000:86589, DN 133:730; M. Sreepriya et al., "Protective effects of L-arginine on experimental myocardial injury induced by β-adrenergic stimulation in rats", Journal of Clinical Biochemistry and Nutrition, 1999, Vol. 27, No. 1, pp. 19-26
- Document 3: J. Basivireddy et al., "Indomethacin-induced mitochondrial dysfunction and oxidative stress in villus enterocytes", Biochemical Pharmacology, 2002, Vol. 64, No. 2, pp. 339-349

Claims 1-6

The inventions set forth in claims 1-6 are not novel and do not involve an inventive step in the light of documents 1-3, cited in the international search report.

Document 1 discloses the protective action of Larginine on myocardial structure. As mentioned in the description, it was also known before the filing date of the present application that dysfunction of the myocardium, etc., is a mitochondrial disorder. Therefore, the use of L-arginine to manage myocardial disorders disclosed in document 1 can naturally also be considered to be treatment of a disorder caused by mitochondrial dysfunction.

Documents 2 and 3 disclose the action of L-arginine in protecting against mitochondrial dysfunction.

Moreover, selection of the dose, treatment period, form of administration and other additional commonly used ingredients in the inventions disclosed in documents 1-3 could be suitably deduced by a person skilled in the art via a process of optimization.